As of 2025-11-01, the Intrinsic Value of Eli Lilly and Co (LLY) is 501.14 USD. This LLY valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 862.86 USD, the upside of Eli Lilly and Co is -41.90%.
The range of the Intrinsic Value is 294.30 - 1,581.63 USD
Based on its market price of 862.86 USD and our intrinsic valuation, Eli Lilly and Co (LLY) is overvalued by 41.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 294.30 - 1,581.63 | 501.14 | -41.9% |
| DCF (Growth 10y) | 384.70 - 1,912.34 | 631.35 | -26.8% |
| DCF (EBITDA 5y) | 176.90 - 211.73 | 195.65 | -77.3% |
| DCF (EBITDA 10y) | 260.95 - 325.33 | 293.47 | -66.0% |
| Fair Value | 243.00 - 243.00 | 243.00 | -71.84% |
| P/E | 248.15 - 695.66 | 405.02 | -53.1% |
| EV/EBITDA | 170.82 - 324.45 | 226.68 | -73.7% |
| EPV | 61.67 - 91.86 | 76.77 | -91.1% |
| DDM - Stable | 276.23 - 1,732.16 | 1,004.20 | 16.4% |
| DDM - Multi | 282.11 - 1,331.73 | 460.86 | -46.6% |
| Market Cap (mil) | 816,662.50 |
| Beta | 0.64 |
| Outstanding shares (mil) | 946.46 |
| Enterprise Value (mil) | 849,377.20 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.97% |
| Cost of Debt | 4.25% |
| WACC | 6.84% |